Mode
Text Size
Log in / Sign up

In adult classic CAH, males show higher obesity rates and BMI than females in Italian cohortAdult men with CAH face higher obesity risks than women

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider sex-specific metabolic risks in adult classic CAH management, as males show higher obesity and visceral adiposity.

This real-world cohort analysis included 123 adult patients (77 females, 46 males) with classic congenital adrenal hyperplasia (CAH) from four Italian tertiary centers. The study compared metabolic outcomes by sex (male vs. female) as the primary exposure.

Males had significantly greater overweight/obesity rates (75.6% vs. 46.7%, p=0.001) and BMI (26.6 vs. 24.4 kg/m², p=0.003) than females. Visceral adiposity, measured by waist-to-height ratio, was also higher in males (0.55 vs. 0.51, p=0.006). Glucocorticoid formulations and total daily doses were comparable between sexes. The rate of uncontrolled disease was 26.2% in males vs. 17.6% in females, but this difference was not statistically significant (p=0.271).

Waist-to-height ratio was the strongest predictor of androstenedione levels (beta=0.311, p=0.003). Among males, visceral adiposity and glucose metabolism abnormalities were critical predictors of poor disease control, a pattern not observed in females.

No adverse events, serious adverse events, discontinuations, or tolerability data were reported. The key limitation is that real-world evidence in adults with CAH remains limited and inconsistent. Practice relevance advocates for prioritizing metabolic health in long-term CAH management, but the observational design limits causal inference.

Imagine waking up tired every morning. You take your medicine, you eat right, and you still feel heavy and sluggish. For many adults living with classic congenital adrenal hyperplasia (CAH), this is not just a bad day. It is a daily reality that changes depending on whether you were born a boy or a girl.

Doctors have known for years that men and women with CAH experience the disease differently. But until now, most evidence came from small groups or older records. A new look at real-world data from four major hospitals in Italy changes how we see this condition.

The Weight Gap Is Real

The study looked at 123 adult patients. The average woman was about 30 years old, and the average man was 32. At first glance, their hormone treatments looked similar. Both groups took the same types of glucocorticoid drugs in comparable daily amounts.

But the numbers tell a different story when it comes to body weight. Three-quarters of the men were overweight or obese. Less than half of the women fell into that category. The average BMI for men was higher, and their waist sizes were larger relative to their height.

This difference is not just about vanity. Excess belly fat, known as visceral adiposity, acts like a silent disruptor. It throws off the body's chemistry. In men, this extra weight makes it harder for doctors to keep hormone levels in the sweet spot.

Why Men Struggle More

Think of your body as a factory trying to balance chemicals. In men with CAH, the factory is often overwhelmed by fat. This fat tissue releases signals that confuse the system. It makes the body resistant to insulin and throws off the production of androstenedione, a key hormone.

For women, the story is different. Estrogen plays a protective role here. It helps keep the metabolic engine running smoother. This natural shield explains why fewer women experience uncontrolled disease compared to men. The gap is not in the medicine they take. It is in how their bodies handle the weight.

Researchers dug deep into the records. They found that waist-to-height ratio was the biggest warning sign. If a man's waist was too big for his height, his hormone control suffered. This link was strong and clear.

In women, the picture was less dramatic. While weight mattered, the protective effect of estrogen kept many women stable even when they carried extra pounds. The study confirmed that metabolic health is the key to long-term success. Without it, the disease remains hard to manage.

The Vicious Cycle

Here is the catch. Being overweight makes the disease harder to control. Having a hard time controlling the disease makes it harder to lose weight. It is a loop that traps many men.

Doctors see this often. A patient comes in with high hormone levels. The doctor adjusts the dose. But if the patient is carrying significant belly fat, the adjustment might not stick. The body simply does not respond the same way it used to.

If you or a loved one has CAH, this news is important. It means treatment plans cannot be one-size-fits-all. A plan that works for a woman might need tweaking for a man.

The good news is that doctors can now spot these risks earlier. By focusing on waist size and metabolic health, doctors can intervene sooner. Lifestyle changes become part of the core treatment, not just an add-on.

This study was a real-world analysis. It used data from patients already in care. This makes the findings very practical. However, there are limits. The group was mostly from Italy. We need to see if these results hold true in other countries with different diets and lifestyles.

Also, the study looked at adults. We do not know yet if these sex differences start in childhood. Researchers are already planning the next steps. They want to test new ways to break the weight-hormone cycle.

This doesn't mean this treatment is available yet.

The goal is simple. We want every patient, regardless of gender, to feel their best. We want to stop the cycle of weight and poor control. By understanding these differences, we can build better bridges to health.

The next phase involves testing specific interventions. Will new drugs help men lose weight and regain control? Can we find ways to boost the protective effects seen in women? Science is moving fast. But patience is required. We must wait for trials to prove safety and effectiveness.

Until then, the message is clear. Pay attention to your waistline. Talk to your doctor about your weight. And remember that your gender matters in how you manage this condition. Knowledge is power, and now we have more of it than ever before.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe phenotypic variability of classic congenital adrenal hyperplasia (CAH) demands tailored management to optimize disease control and attenuate long-term consequences. Although sex-specific differences have been recognized, real-world evidence in adults remains limited and inconsistent. Therefore, this study aimed to compare the clinical, metabolic, and hormonal profiles of adult male and female patients with classic CAH and identify sex-specific predictors of biochemical control.MethodsIn this multicenter, real-world analysis, records from adult CAH patients followed at four Italian tertiary centers, focusing on anthropometry, glucocorticoid (GC) therapy, biochemical and hormonal parameters, were retrospectively collected. Whole cohort and sex-stratified predictors of uncontrolled disease were then identified.ResultsOverall, 123 patients [77 females, 30.5 (24–37) years; 46 males, 32 (23–40) years] were enrolled. Males showed greater overweight/obesity rates (75.6% vs. 46.7%, p = 0.001), BMI (26.6 vs. 24.4 kg/m2, p = 0.003) and visceral adiposity indices [waist-to-height ratio (WHtR) 0.55 vs. 0.51, p = 0.006]. GC formulations and total daily doses were comparable between the sexes. Uncontrolled disease occurred in 26.2% of males and 17.6% of females (p = 0.271). WHtR was the strongest predictor of androstenedione (β = 0.311, p = 0.003). Sex-stratified analysis revealed that visceral adiposity and glucose metabolism abnormalities were critical predictors of poor control among males but not females.ConclusionsAdult males with CAH may face a vicious cycle of adiposity-driven metabolic and hormonal dysregulation, hindering disease control; however, estrogens may counteract these effects in well-controlled females. These results advocate for prioritizing metabolic health for long-term CAH management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.